Introduction
Patients with Systemic Lupus Erythematosus (SLE) face a significantly higher risk of premature atherosclerosis and cardiovascular disease (CVD) compared to the general population. This elevated risk is driven by immune dysregulation, specifically the Type I interferon (IFN) pathway. IFNs stimulate neutrophils to release Neutrophil Extracellular Traps (NETs)—webs of DNA and proteins that, while intended to trap pathogens, cause endothelial damage and impair Cholesterol Efflux Capacity (CEC). This study investigated whether anifrolumab, a monoclonal antibody targeting the Type I IFN receptor, could reverse these pro-inflammatory vascular processes.
Methods
Researchers conducted a post-hoc analysis of the MUSE study, a Phase IIb randomized, double-blind, placebo-controlled trial of anifrolumab. The analysis included 190 patients, stratified by their baseline interferon gene signature (IFNGS) into "high" and "low" categories.
The study measured three specific Neutrophil NET Complexes (NNCs)—MPO-DNA, HNE-DNA, and CitH3-DNA—and assessed Cholesterol Efflux Capacity (CEC). Results from the 300 mg anifrolumab group (n=73) were compared against a placebo group (n=52) and a healthy donor control group (n=20).
Key Insights and Results
The study confirmed a strong link between IFN activity and vascular damage. Circulating NET complexes were significantly higher in SLE patients, particularly those with a high IFNGS.
- NET Reduction: Anifrolumab significantly decreased all three types of circulating NET complexes by Day 365 (p ≤ 0.05), whereas no change was observed in the placebo group.
- Improved Cholesterol Handling: In patients with defective cholesterol efflux and a high IFN signature, anifrolumab significantly increased CEC (p < 0.001).
- Direct Mechanism: The improvement in vascular markers appeared to be a direct result of blocking IFN signaling, as changes in steroid dosages did not correlate with improvements in CEC.
- Baseline Correlation: Higher baseline NET levels were strongly predictive of poor baseline CEC (p < 0.05), reinforcing the theory that NETs actively impair vascular health.
Conclusion and Future Directions
Anifrolumab demonstrates the potential to mitigate vascular inflammation in SLE by reducing NET formation and improving cholesterol handling. While these findings rely on surrogate biomarkers, they suggest that targeting the Type I IFN pathway may reduce the long-term cardiovascular burden in lupus patients. Future studies are needed to confirm if these biological changes translate into a lower clinical incidence of cardiovascular events like heart attacks or strokes.
Summary updated